Based on our deep understanding of endothelial biology, Ingenia found a unique way to halt, reverse and recover blood vessel disorders by modifying a clinically validated signaling pathway. Our target pathway is required for lymphatic and blood vessel development and has a unique role in the control of vascular stability. The pathway controls vascular permeability, inflammation, and pathological angiogenic responses. Microvascular dysfunction and endothelial activation, which are associated with increased endothelial permeability and inflammation, present an important clinical problem in many pathological processes, including vascular complications of diabetes, retinal vascular diseases, inflammatory diseases, cancer, and etc. The re-establishment of a structurally and functionally stable vasculature would be beneficial in these conditions.